Meeting
2022 ASCO Annual Meeting
CK+/CD45+ (dual-positive) circulating cells are associated with prognosis in patients with advanced breast cancer.
Authors
Carolina Reduzzi
Northwestern University - Feinberg School of Medicine, Chicago, IL
Carolina Reduzzi , Lorenzo Gerratana , Youbin Zhang , Paolo D'Amico , Ami N. Shah , Andrew A. Davis , Maroua Manai , Marco Silvestri , Qiang Zhang , Jeannine Donahue , Massimo Cristofanilli
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Other Breast Cancer Subtypes
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1093)
DOI
10.1200/JCO.2022.40.16_suppl.1093
Abstract #
1093
Poster Bd #
470
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Long-term follow up for a phase I trial HER2/neu-targeted T cells in women with advanced breast cancer.
First Author: Lawrence G. Lum
Poster
2013 ASCO Annual Meeting
4EVER: Assessment of circulating tumor cells with a novel, filtration-based method, in a phase IIIb multicenter study for postmenopausal, HER2-negative, estrogen receptor-positive, advanced breast cancer patients.
First Author: Peter A. Fasching
Poster
2011 ASCO Annual Meeting
Redefining CTCs: Detection of additional circulating tumor cells using an antibody capture cocktail and HER2 FISH.
First Author: F. Z. Bischoff
Poster
2011 ASCO Annual Meeting
Correlation of circulating tumor cells in SCCNH patients to cancer reoccurrence using a negative enrichment technology.
First Author: K. Jatana